6/12/2024  9:59:50 PM Chg. +0.40 Volume Bid- Ask- Market Capitalization Dividend Y. P/E Ratio
59.91USD +0.66% 98,457
Turnover: 5.91 mill.
-Bid Size: - -Ask Size: - 13.46 bill.USD - 22.45

Business description

Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics.
 

Management board & Supervisory board

CEO
Hervé Hoppenot
Management board
Christiana Stamoulis, Paula J. Swain, Pablo J. Cagnoni, Steven H. Stein, M.D., Maria E. Pasquale, Dr. Lothar H. Finke, Barry P. Flannelly, Denise Brashear, Vijay Iyengar, M.D., Jonathan E. Dickinson, Michael Morrissey, Xiaozhao Wang
Supervisory board
Hervé Hoppenot, Julian C. Baker, Jean-Jacques Bienaimé, Otis Brawley, M.D., Paul J. Clancy, Dr. Jacqualyn A. Fouse, Edmund P. Harrigan, M.D., Katherine High, M.D., Susanne Schaffert
 

Company data

Name: Incyte Corporation
Address: 1801 Augustine Cut-Off,Wilmington, DE 19803, USA
Phone: +1-302-498-6700
Fax: -
E-mail: -
Internet: www.incyte.com/
Industry: Biotechnology
Sector: Biotechnology
Sub sector: Biotechnology
End of financial year: 12/31
Free Float: 41.80%
IPO date: -

Investor relations

Name: Ben Strain
IR phone: +1-302-274-4779
IR Fax: -
IR e-mail: IR@incyte.com

Main Shareholders

Others
 
38.69%
Baker Brothers Advisors, LLC
 
16.22%
Vanguard Group, Inc.
 
9.75%
Blackrock Inc.
 
9.25%
Dodge & Cox Inc
 
8.67%
Royal Bank of Canada
 
5.68%
State Street Corporation
 
4.18%
Renaissance Technologies, LLC
 
2.51%
Invesco Ltd.
 
1.82%
Others
 
3.23%